Table 2.

Association between myasthenia gravis and labour market participation during 1- and 2-years follow up

	No LMP, n (%)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)a
Comparison groups	No LMP, 1 year after diagnosis/match
MG vs. matched references	35 (10.6)/309 (4.7)	2.42 (1.67–3.49)	2.23 (1.46–3.38)
MG: age 40+ vs. 18–39	22 (11.2)/13 (9.7)	1.18 (0.57–2.43)	2.02 (0.84–4.86)
MG: male vs. female	10 (7.7)/25 (12.5)	0.58 (0.27–1.26)	0.67 (0.28–1.59)
MG: AChEI+ vs. AChEI	21 (12.2)/14 (8.9)	1.43 (0.70–2.92)	1.26 (0.57–2.78)
Comparison groups	No LMP, 2 years after diagnosis/match
MG vs. matched references	75 (22.7)/327 (5.0)	5.64 (4.26–7.47)	5.76 (4.13–8.04)
MG: age 40+ vs. 18–39	44 (22.5)/31 (23.1)	0.96 (0.57–1.62)	1.21 (0.64–2.27)
MG: male vs. female	19 (14.6)/56 (28.0)	0.44 (0.25–0.78)	0.39 (0.20–0.74)
MG: AChEI+ vs. AChEI	49 (28.5)/26 (16.5)	2.02 (1.18–3.45)	1.95 (1.09–3.50)

Abbreviations: LMP labour market participation, MG myasthenia gravis, AChEI Acetylcholinesterase inhibitors, AChEI+ AChEI + immunosuppression. OR odds ratio, CI confidence interval

^aAdjusted for age, gender, profession, marital status, pharmacological treatment, sick leave 1 year before diagnosis/match, and time period